Credit Suisse’s Myovant Sciences Ltd. MYOV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-233,976
| Closed | -$6.31M | – | 3923 |
|
|
2022
Q4 | $6.31M | Buy |
233,976
+197,360
| +539% | +$5.19M | 0.01% | 1162 |
|
|
2022
Q3 | $657K | Buy |
36,616
+7,709
| +27% | +$123K | ﹤0.01% | 2625 |
|
|
2022
Q2 | $359K | Buy |
28,907
+2,593
| +10% | +$28.6K | ﹤0.01% | 3056 |
|
|
2022
Q1 | $350K | Buy |
26,314
+1,659
| +7% | +$22.2K | ﹤0.01% | 3155 |
|
|
2021
Q4 | $383K | Sell |
24,655
-1,987
| -7% | -$37.9K | ﹤0.01% | 4001 |
|
|
2021
Q3 | $598K | Buy |
26,642
+587
| +2% | +$12.9K | ﹤0.01% | 3699 |
|
|
2021
Q2 | $586K | Sell |
26,055
-6,235
| -19% | -$131K | ﹤0.01% | 3747 |
|
|
2021
Q1 | $664K | Buy |
32,290
+4,777
| +17% | +$109K | ﹤0.01% | 3582 |
|
|
2020
Q4 | $760K | Sell |
27,513
-27,786
| -50% | -$541K | ﹤0.01% | 3538 |
|
|
2020
Q3 | $777K | Buy |
55,299
+36,300
| +191% | +$675K | ﹤0.01% | 3117 |
|
|
2020
Q2 | $392K | Sell |
18,999
-11
| -0.1% | -$150 | ﹤0.01% | 3458 |
|
|
2020
Q1 | $143K | Buy |
19,010
+2,808
| +17% | +$31.5K | ﹤0.01% | 3746 |
|
|
2019
Q4 | $251K | Buy |
16,202
+1,318
| +9% | +$13.3K | ﹤0.01% | 3904 |
|
|
2019
Q3 | $78K | Buy |
14,884
+4,744
| +47% | +$35.2K | ﹤0.01% | 3989 |
|
|
2019
Q2 | $92K | Buy |
+10,140
| New | +$151K | ﹤0.01% | 3958 |
|
|
2017
Q3 | – | Sell |
-13,222
| Closed | -$155K | – | 4284 |
|
|
2017
Q2 | $155K | Buy |
+13,222
| New | +$164K | ﹤0.01% | 3670 |
|
Other funds holding MYOV
Credit Suisse's MYOV Position: Q1 2023 in Review
Credit Suisse sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 233,976 shares — an estimated $6.31M sold.
Credit Suisse first reported a position in MYOV in Q2 2017 and held it in 16 quarters. The position peaked at $6.31M in Q4 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.
- Credit Suisse reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
- Credit Suisse sold 233,976 Myovant Sciences Ltd. shares in Q1 2023, an estimated $6.31M.
- Credit Suisse first reported a position in Myovant Sciences Ltd. in Q2 2017 and held it in 16 quarters.
- Credit Suisse's Myovant Sciences Ltd. position peaked at $6.31M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.
Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.